2020
Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective?
Torres M, Bodini G, Furnari M, Marabotto E, Zentilin P, Strazzabosco M, Giannini EG. Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective? Cancers 2020, 12: 1422. PMID: 32486355, PMCID: PMC7352281, DOI: 10.3390/cancers12061422.Peer-Reviewed Original ResearchLiver diseaseHepatocellular carcinomaRisk factorsHCC surveillanceNAFLD patientsNon-alcoholic fatty liver diseasePrevalence of HCCFrequent primary liver cancerNon-alcoholic fatty liverNon-cirrhotic NAFLDNon-cirrhotic subjectsCause of cirrhosisTreatment of HBVChronic liver diseaseFatty liver diseasePrimary liver cancerCancer-related deathMain risk factorsGood clinical judgmentEarly HCC detectionDeaths/yearNew screening toolNAFLD epidemicHCV infectionLiver ultrasonography
2019
Clinical outcome indicators in chronic hepatitis B and C: A primer for value‐based medicine in hepatology
Strazzabosco M, Cortesi P, Conti S, Okolicsanyi S, Rota M, Ciaccio A, Cozzolino P, Fornari C, Gemma M, Scalone L, Cesana G, Fabris L, Colledan M, Fagiuoli S, Ideo G, Zavaglia C, Perricone G, Munari L, Mantovani L, Belli L. Clinical outcome indicators in chronic hepatitis B and C: A primer for value‐based medicine in hepatology. Liver International 2019, 40: 60-73. PMID: 31654608, PMCID: PMC10916792, DOI: 10.1111/liv.14285.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntiviral AgentsCarcinoma, HepatocellularFemaleGastroenterologyHepatitis B, ChronicHepatitis C, ChronicHumansItalyLiver CirrhosisLiver NeoplasmsLongitudinal StudiesMaleMiddle AgedProspective StudiesQuality Indicators, Health CareSurvival AnalysisTreatment OutcomeValue-Based Health InsuranceConceptsClinical outcome indicatorsClinical practiceOutcome indicatorsChronic hepatitis BClinical practice settingMajor health problemCurrent international guidelinesNew effective treatmentsValue of careMETHODS/RESULTSHCV patientsHCV infectionHepatitis BClinical outcomesLiver diseaseMulticentre studyEffective treatmentHealth problemsInternational guidelinesCare deliveryValue-based medicineCostly treatmentPractice settingsHBVPatients
2018
Delisting of Liver Transplant Candidates with Chronic HCV Infection after Viral Erradication
Vinaixa C, Belli L, Berenguer M, Cortesi P, Strazzabosco M, Faccheti R, Rockenschaub S, Martini S, Morelli C, Donato F, Volpes R, Pasulo L, Pageaux G, Coilly A, Perricone G, Mazzarelli C, Di Nicola S, Berlakovich G, Duvuox C. Delisting of Liver Transplant Candidates with Chronic HCV Infection after Viral Erradication. Transplantation 2018, 102: s3. DOI: 10.1097/01.tp.0000542536.91165.49.Peer-Reviewed Original ResearchDirect acting antiviralsMedian Child-PughHepatocellular carcinomaChild-PughMedian followLiver transplantationMELD scoreClinical improvementSecond generation direct acting antiviralsClinical outcome 2 yearsDevelopment of HCCIntestine Transplant AssociationChronic HCV infectionLiver transplant candidatesLiver function testsStart of therapySignificant clinical improvementRisk of deathOutcomes 2 yearsDAA therapyEuropean LiverDecompensated cirrhosisHCV infectionAbdominal ultrasoundActing antiviralsLBP-021 The percentage of patients with HCV infection in need of a liver transplant is rapidly declining while their survival after transplantation is improving: A study based on European liver transplant registry
Perricone G, Mazzarelli C, Viganò R, Duvoux C, Cortesi P, Facchetti R, Vangeli M, Karam V, Adam R, Strazzabosco M, Belli L. LBP-021 The percentage of patients with HCV infection in need of a liver transplant is rapidly declining while their survival after transplantation is improving: A study based on European liver transplant registry. Journal Of Hepatology 2018, 68: s116. DOI: 10.1016/s0168-8278(18)30448-3.Peer-Reviewed Original Research
2017
ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients
Belli LS, Duvoux C, Berenguer M, Berg T, Coilly A, Colle I, Fagiuoli S, Khoo S, Pageaux GP, Puoti M, Samuel D, Strazzabosco M. ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients. Journal Of Hepatology 2017, 67: 585-602. PMID: 28323126, DOI: 10.1016/j.jhep.2017.03.006.Peer-Reviewed Original ResearchConceptsLiver transplantationHCV infectionConsensus statementUse of DAAsLiver transplant candidatesLiver transplant recipientsSevere renal failureRemarkable clinical improvementTransplant recipientsClinical improvementLT candidatesRenal failureTransplant candidatesDisease recurrenceNative liverUnusual complicationTransplant fieldDrug interactionsHCV- graftsWaiting listAntiviral agentsRecipientsHCVPatientsGraft
2011
Impact of HCV Infection on Graft Survival After Liver Transplantation for Hepatocellular Carcinoma in Compensated Cirrhosis: The Liver Match Cohort Study
Angelico M, Cillo U, Fagiuoli S, Strazzabosco M, Gasbarrini A, Romagnoli R, Nardi A. Impact of HCV Infection on Graft Survival After Liver Transplantation for Hepatocellular Carcinoma in Compensated Cirrhosis: The Liver Match Cohort Study. Gastroenterology 2011, 140: s-901. DOI: 10.1016/s0016-5085(11)63738-4.Peer-Reviewed Original Research